Egetis Therapeutics launches EMCITATE in the US for MCT8 deficiency

Egetis Therapeutics has initiated the US commercial launch of EMCITATE, the first and only FDA-approved therapy for peripheral thyrotoxicosis in adult and pediatric patients with MCT8 deficiency. The company also introduced Egetis RareLink, a patient support program developed with PANTHERx Rare Pharmacy.

Detected & updated continuously · Source: Nebula